Sanofi and GSK to provide UK with 60m doses of Covid-19 vaccine
French pharmaceutical giant Sanofi and GlaxoSmithKline have agreed to provide the UK with as many as 60.0m doses of their Covid-19 vaccine candidate, subject to final contract.
CAC 40
7,355.37
17:00 27/12/24
1.00%
72.68
DJ EURO STOXX 50
4,898.88
23:59 27/12/24
0.84%
41.02
FTSE 100
8,149.78
16:54 27/12/24
n/a
n/a
FTSE 350
4,495.62
16:29 27/12/24
n/a
n/a
FTSE All-Share
4,453.14
17:05 27/12/24
n/a
n/a
GSK
1,342.50p
17:00 27/12/24
0.22%
3.00p
Pharmaceuticals & Biotechnology
20,065.81
16:29 27/12/24
0.00%
20,065.81
Sanofi
€93.28
16:40 27/12/24
1.67%
€1.53
The vaccine candidate employs a combination of Sanofi's recombinant protein-based technology and GSK's pandemic adjuvant technology.
Both firms also reiterated their commitment to making both drugs available globally.
GlaxoSmithKline was scheduled to report second quarter sales at noon the same day.